%PDF-1.4
%
41 0 obj
<>
endobj
38 0 obj
<>
endobj
90 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-02-06T10:01:48Z
2024-03-29T05:38:03-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T05:38:03-07:00
application/pdf
Heather
2003-819.marchsupl.69
uuid:1139bcba-1dd2-11b2-0a00-1d0a275d6100
uuid:1139bcbe-1dd2-11b2-0a00-aa0000000000
endstream
endobj
27 0 obj
<>
endobj
28 0 obj
<>
endobj
42 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 13 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 15 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 17 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 19 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
108 0 obj
[112 0 R]
endobj
109 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 354.2144 35.9844 Tm
[(The Journal of Rheumatology 2004, V)110.7 (olume 31, Supplement 69)]TJ
0 Tc 0 Tw -37.5268 -0.0313 Td
(26)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.09 396.47 -10.83 re
f*
0.5 w
109.25 59.09 396.47 -10.83 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
-0.00011 Tc 0.14349 Tw 10 0 0 10 54 713.1616 Tm
(and drug therapy recorded by the physician, and nondrug)Tj
0.26849 Tw 0 -1.2 TD
(therapies, as well as the outcomes pain, function, early)Tj
0.0762 Tw T*
(retirement, etc., recorded by the patient \321 are the same in)Tj
-0.0172 Tw T*
[(all cohorts. Identical scales are used wherever possible. )17.7 (This)]TJ
0.2355 Tw T*
(has an important advantage: outcomes can be compared)Tj
0.02499 Tw T*
[(across dif)17.7 (ferent cohorts and diagnoses. )]TJ
/T1_3 1 Tf
0 Tw 0 -2.4 TD
(CONCLUSION)Tj
/T1_2 1 Tf
0.29269 Tw 0 -1.2 TD
(The national database is an important tool for German)Tj
0.0383 Tw T*
[(rheumatology)64.8 (. It is, however)39.7 (, not a longitudinal database in)]TJ
0.1571 Tw T*
(the sense of complete individual followup of all patients.)Tj
0.1891 Tw T*
(This would not be feasible given the number of patients)Tj
0.185 Tw T*
[(included per year)54.8 (. Complete followup is restricted to the)]TJ
0.1244 Tw T*
(specific cohorts described here. It should be kept in mind)Tj
0.043 Tw T*
(that the database has been performing successfully now for)Tj
0.04289 Tw T*
(10 years, and its existence has been a prerequisite for other)Tj
0.0592 Tw T*
(kinds of databases, of which the most recent is the registry)Tj
0.02499 Tw T*
(of biologics noted above.)Tj
0.20599 Tw 1.2 -1.2 Td
(Still, these documentation components are pencil-and-)Tj
0.0336 Tw -1.2 -1.2 Td
[(paper based. )17.7 (T)69.9 (o date this has been the only way to enable a)]TJ
0.0239 Tw T*
[(great number of rheumatologists with very dif)17.7 (ferent experi-)]TJ
0.1167 Tw T*
(ences and electronic data processing equipment to partici-)Tj
0.0199 Tc 0.3575 Tw T*
[(pate. )54.8 (A)-572.6 (group at the University of Duesseldorf \(M.)]TJ
-0.00011 Tc 0.3439 Tw T*
(Schneider\) will provide German rheumatology with an)Tj
0.0085 Tc 0.36639 Tw T*
(Internet-based client-server tool for registration of all)Tj
-0.00011 Tc 0.02499 Tw T*
(patient data.)Tj
/T1_3 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_2 1 Tf
0.2758 Tw 8 0 0 8 54 379.1616 Tm
(The establishment and continuation of the database would have been)Tj
0.0706 Tw 0 -1.25 TD
[(impossible without the enthusiasm and unpaid work of a lar)17.7 (ge number of)]TJ
-0.00211 Tw T*
(German rheumatologists: Collaborative arthritis centers and their speake\
rs:)Tj
-0.0208 Tw T*
[(Aachen/Koeln/ Bonn: E. Genth, Berlin: J. Sieper)39.7 (, Dresden: H.E. Schroeder)39.7 (,)]TJ
0.0199 Tc 0.6366 Tw T*
[(Duesseldorf: M. Schneider)39.8 (, Erlangen: B. Swoboda, )17.8 (W)79.9 (estliches)]TJ
0.00301 Tc 0.3719 Tw T*
[(Ruhr)17.7 (gebiet/Essen: C. Specker)39.7 (, Giessen/Bad Nauheim: K.L. Schmidt,)]TJ
-0.00011 Tc 0.21519 Tw T*
[(Greifswald: H. Merk, Hannover: H. Zeidler)39.7 (, Heidelber)17.7 (g: U. Schneider)39.7 (,)]TJ
0.20959 Tw T*
[(Jena: G. Hein, Leipzig: H. Haentzschel, Luebeck/Bad Bramstedt: )17.7 (W)91.9 (.L.)]TJ
0.0128 Tc 0.36211 Tw T*
[(Gross, Magdebur)17.9 (g/V)128.9 (ogelsang: J. Kekow)65 (, Mainz/Bad Kreuznach: R.)]TJ
0.0199 Tc 0.5175 Tw T*
[(Dreher)39.7 (, Muenchen: M. Schattenkirchner)39.8 (, Muenster: M. Gaubitz,)]TJ
-0.00011 Tc 0.3181 Tw T*
[(Ostwestfalen/Lippe: H. Mielke, Regensbur)17.7 (g/Bad )54.9 (Abbach: U. Mueller)19.7 (-)]TJ
0.10291 Tw T*
[(Ladner)39.7 (, Rhein-Main: J.P)110.7 (. Kaltwasser)39.7 (, Rostock: M. Keysser)39.7 (, Saarland: M.)]TJ
0.02499 Tw T*
[(Pfreundschuh, Suedbaden: H.H. Peter)39.7 (, Suedwuerttember)17.7 (g: R. Maleitzke.)]TJ
/T1_1 1 Tf
0.3257 Tw 0 -1.85 TD
[(Speakers of the working gr)36.8 (oup of collaborative arthritis centers:)]TJ
/T1_2 1 Tf
0 Tw 29.0281 0 Td
(H.)Tj
0.0045 Tw -29.0281 -1.25 Td
[(Zeidler)39.7 (, Hannover 1993-2002 and M. Schneider)39.7 (, Duesseldorf \(since 2003\).)]TJ
0.0448 Tw 0 -1.25 TD
(The national database was initiated in 1992 by E. Genth, H.H. Raspe, and\
)Tj
0.02499 Tw T*
(A. Zink.)Tj
0.0493 Tw 1.5 -1.25 Td
[(Data analyses were performed by J. Listing, S. Ziemer)39.7 (, K. )17.8 (Thiele, and)]TJ
0.2729 Tw -1.5 -1.25 Td
(M. Niewerth from the German Rheumatism Research Centre and the)Tj
0 Tw T*
(authors.)Tj
/T1_3 1 Tf
10 0 0 10 54 160.3616 Tm
(REFERENCES)Tj
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 61 150.3615 Tm
[(1. )-600.1 (Zink )54.8 (A, Listing J, Niewerth M, Zeidler H, for the German)]TJ
1.675 -1.25 Td
[(Collaborative )54.8 (Arthritis Centres. )17.7 (The National Database of the)]TJ
T*
[(German Collaborative )54.8 (Arthritis Centres \321 treatment of patients)]TJ
T*
[(with rheumatoid arthritis. )54.8 (Ann Rheum Dis 2001;60:207-13.)]TJ
-1.675 -1.25 Td
[(2. )-600.1 (Zink )54.8 (A, Listing J, Klindworth C, Zeidler H, for the German)]TJ
1.675 -1.25 Td
[(Collaborative )54.8 (Arthritis Centres. )17.7 (The National Database of the)]TJ
T*
[(German Collaborative )54.8 (Arthritis Centres. Structure, aims, and)]TJ
0 Tc T*
[(patients. )54.9 (Ann Rheum Dis 2001;60:199-206.)]TJ
-0.00011 Tc 31.325 79.271 Td
[(3. )-600.1 (Zink )54.8 (A, German Collaborative )54.8 (Arthritis Centres. Die)]TJ
1.675 -1.25 Td
(Kerndokumentation als Instrument zur Erfassung, Steuerung und)Tj
T*
[(Qualitaetssicherung neuer )17.7 (Therapien der rheumatoiden )54.8 (Arthritis)]TJ
T*
(\(National database documentation for collecting, controlling and)Tj
T*
(quality assurance of new therapies in rheumatoid arthritis\). )Tj
T*
(Z Rheumatol 2001;60:469-72.)Tj
-1.675 -1.25 Td
[(4. )-600.1 (Zink )54.8 (A, Braun J, Listing J, )17.7 (W)79.9 (ollenhaupt J. Disability and handicap)]TJ
1.675 -1.25 Td
(in rheumatoid arthritis and ankylosing spondylitis \321 Results from)Tj
T*
(the German rheumatological database. J Rheumatol 2000;)Tj
0 Tc 0 Tw T*
(27:613-22.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5. )-600.1 (Minden K, Niewerth M, Listing J, Zink )54.8 (A, the pediatricians of the)]TJ
1.675 -1.25 Td
(German study group of pediatric rheumatologists. Health care)Tj
T*
(provision in pediatric rheumatology in Germany \321 national)Tj
T*
(rheumatologic database. J Rheumatol 2002;29:622-8.)Tj
-1.675 -1.25 Td
[(6. )-600.2 (Steinbrocker O, )17.6 (T)35 (raeger CH, Battermann RC. )17.6 (Therapeutic criteria)]TJ
1.675 -1.25 Td
[(in rheumatoid arthritis. JAMA)-220.2 (1949;140:659-62.)]TJ
-1.675 -1.25 Td
[(7. )-600.1 (Prevoo ML, van\325)17.7 (t Hof MA, Kuper HH, van Leeuwen MA, van de)]TJ
1.675 -1.25 Td
(Putte LB, van Riel PL. Modified disease activity scores that include)Tj
T*
(twenty-eight-joint counts. Development and validation in a)Tj
T*
(prospective longitudinal study of patients with rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1995;38:44-8.)Tj
-1.675 -1.25 Td
[(8. )-600.1 (Zeidler H. )17.7 (T)69.9 (erminologie und Klassifikation. In: Zeidler H, Zacher J,)]TJ
1.675 -1.25 Td
[(Hiepe F)79.7 (, editors. Interdisziplinaere klinische Rheumatologie.)]TJ
T*
(Berlin: Springer; 2001:531-41.)Tj
-1.675 -1.25 Td
[(9. )-600.1 (Lautenschlaeger J, Mau )17.7 (W)91.8 (,)-0.1 ( Kohlmann )17.7 (T)74 (, et al. )17.7 (V)110.8 (e)0.3 (r)17.7 (gleichende)]TJ
1.675 -1.25 Td
[(Evaluation einer deutschen )17.7 (V)110.8 (ersion des Health )54.8 (Assessment)]TJ
T*
(Questionnaires \(HAQ\) und des Funktionsfragebogens Hannover)Tj
T*
(\(FFbH\). [Comparative evaluation of a German version of the)Tj
T*
[(Health )54.8 (Assessment Questionnaire \(HAQ\) and the Hanover)]TJ
T*
(Functional Status Questionnaire \(HFSQ\)]. Z Rheumatol)Tj
0 Tc 0 Tw T*
(1997;56:144-55.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10. )-600.1 (W)79.9 (esthof)17.7 (f G, Listing J, Zink )54.8 (A. Loss of physical independence in)]TJ
2.175 -1.25 Td
(rheumatoid arthritis: Interview data from a representative sample of)Tj
T*
[(patients treated in tertiary rheumatologic care. )54.8 (Arthritis Care Res)]TJ
0 Tc 0 Tw T*
[(2000;13:1)36.9 (1-21.)]TJ
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1. )-600.1 (Zink )54.8 (A, Braun J, Listing J, )17.7 (W)79.9 (ollenhaupt J. Disability and handicap)]TJ
2.1381 -1.25 Td
(in rheumatoid arthritis and ankylosing spondylitis \321 results from)Tj
T*
(the German rheumatological database. J Rheumatol 2000;)Tj
0 Tc 0 Tw T*
(27:613-22.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12. )-600.1 (Fischer R, Listing J, Specker C, Schneider M, Zink )54.8 (A. Longterm)]TJ
2.175 -1.25 Td
(functional and social outcome in systemic lupus erythematosus and)Tj
T*
(rheumatoid arthritis \321 results from the German rheumatological)Tj
T*
[(database [abstract]. )54.8 (Arthritis Rheum 2001;44 Suppl:S291.)]TJ
-2.175 -1.25 Td
[(13. )-600.1 (Mau )17.7 (W)91.9 (, Listing J, Zeidler H, Zink )54.8 (A, the German Collaborative)]TJ
2.175 -1.25 Td
(Arthritis Centres. Standardized employment rates in chronic)Tj
T*
[(inflammatory rheumatic diseases [abstract]. )54.8 (Arthritis Rheum)]TJ
0 Tc T*
(2000;43 Suppl:S163.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(14. )-600.1 (Mau )17.7 (W)91.9 (, Listing J, Zeidler H, Zink )54.8 (A, the German Collaborative)]TJ
2.175 -1.25 Td
[(Arthritis Centres Hannover and Berlin. )17.7 (The influences of labor)]TJ
T*
(market conditions, education and gender in the employment in)Tj
T*
[(chronic inflammatory rheumatic diseases [abstract]. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2001;44 Suppl:s188.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15. )-600.1 (Huscher D, )17.7 (Thiele K, Merkesdal S, Zeidler H, Zink )54.8 (A, German)]TJ
2.175 -1.25 Td
[(Collaborative )54.8 (Arthritis Centres. Comparison of the annual direct)]TJ
T*
(and indirect costs in arthritis, ankylosing spondylitis and psoriatic)Tj
T*
[(arthritis [abstract]. )54.8 (Arthritis Rheum 2002;46 Suppl:S93. )]TJ
-2.175 -1.25 Td
[(16. )-600.1 (Zink )54.8 (A. Frequency of refractory rheumatoid arthritis. German)]TJ
2.175 -1.25 Td
[(Society of Rheumatologists, )54.8 (Annual Meeting, Leipzig, September)]TJ
0 Tc T*
(19-22, 2001.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(17. )-600.1 (Zink )54.8 (A, Listing J, Ziemer S, Zeidler H, for the German)]TJ
2.175 -1.25 Td
[(Collaborative )54.8 (Arthritis Centres. Practice variation in the treatment)]TJ
T*
(of rheumatoid arthritis among German rheumatologists. )Tj
T*
(J Rheumatol 2001;28:2201-8.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
21 0 obj
<>stream
8;Z\6!H-pO%+G5@W:(]aS"pbAM/B'+h-o#6Uoc.G'LgdT2h'eZ$Cf$/2f47urOK<@
_u#3o6fti"O.fnZF/g1YtKCV/=>=q5-Wri5:^aTFrF8R&aiDLQ10sn-51Feaj\p
mMkiXPM)7c"E?k#dYT3H#AnQQ-:dNV2Ehi`4BNCIJ:YGpm<3I!3bp5Y-?d62_H&LE
T=#F_kpKsA='s&&kT46:R-pE3BhW>+2uXl/fU!^M?pmr1;gjr^Gil(#eJFu"FK-&t
hr(O38:(%K?7s#pEd;d&jSq_mMZ.-sgGQ/&q#&Ujj0Q=]MEJ.'(4$(!_L4NjFai6"
3:3K?e/sQ\>e9+>$>HW?2<#05RZi&E]*q`$5q$IVP87I,d+A!CT1L<#C6`9K[oZ6'RiG_n$u@p..k
VAS"F?JFJB%%VT*Xkm-%(GaO6`-Yab])j%A=i_iZnTB&f`VZYARX?Tto<%ni\fA4\
OX*&RNfb<#M5T9DFO;ZqS:Djp99^\`V,Zs!^Rre/l#8b"SQ,20BiRn?SZZM=!1'qQ
gAiPC*VZET=7=8M3"P@>T:iPQ&'4ko^co6E%\#=K6e?Hi+poiVI84sVbGh%?(;@oh
Rm@u^Q*LEnHQFpPl<'hN>,'m+aa$)J5g,1H1UFsC+[R[Q!;Zl5"Gi>1q$IB(tbkTo^AhCnO0pJB>d
^1.)\)>NO7p>_D`%iKjPb`Z$u4o]6>5954X!0Nechu~>
endstream
endobj
25 0 obj
[/Indexed/DeviceRGB 255 24 0 R]
endobj
24 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
79 0 obj
<>
endobj
45 0 obj
<>
endobj
48 0 obj
<>
endobj
52 0 obj
<>
endobj
68 0 obj
<>
endobj
95 0 obj
<>
endobj
53 0 obj
<>
endobj
58 0 obj
<>stream
H\T{TWf.n5LD'9.j<*.JDj[P"! $*# ڊ.Uq=]c[Ztx;陜{r~}ߏ$&:>`.]ke'KAJ&' #V.#Ga2ιu:SBu )2ٔ[`>VRal&C=S`rfHD|>`_:SO
Կ9nQ/gp
'x)ȇǷ"g-
OkB4IEc@t}ʣVc-ۖ[X:ӐL
y*\ٮ"B:~R}m5Vv&''xE)4b.8TK? ;mg^ˣhWB+<ݚ>/&D0_jc8
|p4Դ0 .5~{XEb'4E]{Jx==`FW;\g],svNеsvi{Yc%%Gw-`[P|uTH'W,MrJ@rt:9tUoŋfpU'D_pe{{Bҗ5n=pb2$fRGVXKD)+sμj|EPCDtۗmd2c PTdHbi֕W҇JkP82o+`⁇hؾ(
&V բ.G5:nHCC tn[386R@mB=+9Wrex$q,CxWz樛E1^#ZV7_jUBrko0։'(p HAlK%Ql,tGX>FDYX=ET}{E4ݳTnZKvIG}pIMwx
(Ƹk.V2ǿp8T%hZ